Sevion Therapeutics Inc (OTCBB - OTCQB:SNTI)

Data as of Sep 19
 -0.01 / -0.62%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

Senesco Technologies, Inc. is a development stage company, which develops cancer therapeutics products. It has developed eukaryotic translation initiation Factor 5A technology to regulate cell death and survival. The company focuses on portfolio with other potential eukaryotic translation initiation Factor 5A applications in cancer, inflammation and ischemia. It has developed therapeutic candidate, SNS01-T for the potential treatment of multiple myeloma. The company was founded on September 30, 1999 and is headquartered in Bridgewater, NJ.

Contact Information

Senesco Technologies, Inc.
721 Route 202/206
Bridgewater New Jersey 08807-1760
P:(908) 864-4444
Investor Relations:



Individual stakeholders9.82%
Other institutional0.00%
Mutual fund holders0.00%

Top Executives

Ronald A. MartellChief Executive Officer & Director
Leslie J. BrownePresident
Joel P. BrooksChief Financial Officer, Secretary & Treasurer
James Joseph GrazianoChief Technology Officer
Vaughn V. SmiderDirector & Chief Scientific Officer

To view my watchlist

Not a member yet?

Sign up now for a free account
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.